6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Dated January 29, 2007

Lorus Therapeutics Inc. 

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F T Form 40-F ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No T

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Lorus Therapeutics Inc.
Date: January 29, 2007	By:	/s/ Mark Preston
		Mark Preston
		Controller

EXHIBIT LIST

99.1 News Release dated January 26, 2007 - Lorus Responds to Market Activity

EX-99.1

Exhibit 99.1

News release via Canada NewsWire, Toronto 416-863-9350

    Attention Business Editors:
    Lorus responds to market activity

    TORONTO, Jan. 26 /CNW/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR;
AMEX: LRP), a biopharmaceutical company specializing in the research and
development of pharmaceutical products and technologies for the management of
cancer, announced today, at the request of the Toronto Stock Exchange, that
Lorus is not in receipt of material information that would account for the
current market activity of Lorus' shares.

    About Lorus

    Lorus is a publicly traded biopharmaceutical company focused on the
research and development of novel therapeutics in cancer. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory expertise by
developing new drug candidates that can be used, either alone, or in
combination, to successfully manage cancer. Through its own discovery efforts
and an acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus has completed one Phase II and one Phase III
clinical trial. Lorus has several product candidates in multiple Phase II
clinical trials. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR, and on the American Stock Exchange under the
symbol LRP.

    Forward Looking Statements

    This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include, but are
not limited to, statements relating to: our expectations regarding future
financings, our plans to conduct clinical trials, the successful and timely
completion of clinical studies and the regulatory approval process, our plans
to obtain partners to assist in the further development of our product
candidates, the establishment of corporate alliances, the Company's plans,
objectives, expectations and intentions and other statements including words
such as "continue", "believe", "plan", "expect", "intend", "will", "should",
"may", and other similar expressions. Such statements reflect our current
views with respect to future events and are subject to risks and uncertainties
and are necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties and
contingencies. Many factors could cause our actual results, performance or
achievements to be materially different from any future results, performance,
or achievements that may be expressed or implied by such forward-looking
statements, including, among others: our ability to obtain the capital
required for research and operations; the regulatory approval process; the
progress of our clinical trials; our ability to find and enter into agreements
with potential partners; our ability to attract and retain key personnel;
changing market conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports and annual
filings with Canadian securities regulators and the United States Securities
and Exchange Commission.
    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our Annual
Report underlying those forward-looking statements prove incorrect, actual
results may vary materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do not intend,
and do not assume any obligation, to update these forward-looking statements,
except as required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements. Investors are cautioned
that forward-looking statements are not guarantees of future performance and
accordingly investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
    Lorus Therapeutics Inc.'s recent press releases are available through the
Company's website at www.lorusthera.com.

    %SEDAR: 00002368E          %CIK: 0000882361

    /For further information: Investor Relations: Lorus Therapeutics, Inc.,
Dr. Saeid Babaei, Phone: (416) 798-1200, x490, ir(at)lorusthera.com/
    (LOR. LRP)

CO:  Lorus Therapeutics Inc.

CNW 14:57e 29-JAN-07